ArticleBiochemistry and biophysics reports2026
Long-read transcriptomic profiling of a glioma cell line following m6A regulator perturbations.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyladenosine (m6A) is the most prevalent internal mRNA modification and is enriched in the central nervous system (CNS), yet its role in glioma remains incompletely defined. Using long-read direct RNA sequencing, we mapped transcriptome-wide m6A modifications in a single glioma cell line following targeted knockdown of the m6A reader IGF2BP2, writer METTL3, and eraser ALKBH5. Across perturbations, the global architecture of m6A, including transcript class, positional enrichment, and site multiplicity, was largely preserved, while differential methylation was weakly coupled to gene expression. In contrast, m6A regulator perturbation coincided with widespread isoform switching and with changes in untranslated regions, coding potential, and predicted transcript fate, largely independent of bulk gene expression changes. Public glioma datasets further supported the relevance of isoform-specific changes in glioma. Together, these findings highlight isoform-level transcript variation associated with m6A regulator perturbation and support the use of long-read, isoform-resolved approaches to study RNA regulatory states in glioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.